RS4;11人急性B淋巴細(xì)胞白
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/2/12 11:00:28
- 訪問(wèn)次數(shù) 14
聯(lián)系方式：陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息，謝謝!
產(chǎn)品名稱：RS4;11人急性B淋巴細(xì)胞白血病細(xì)胞、RS4;11人急性B淋巴細(xì)胞白血病細(xì)胞,、RS4;11人急性B淋巴細(xì)胞白血病細(xì)胞,、RS4;11人急性B淋巴細(xì)胞白血病細(xì)胞,； 
Combination of PD-L1 positive TILs and SII could further refine prognosis in GCTs.An important aspect of malignant progression is the acquired ability of tumor cells to avoid recognition and destruction by the immune system (immune escape). Clinical cancer progression is also associated with the development of tumor hypoxia, which is mechanistically linked to the
人急性淋巴白血病細(xì)胞RS4:11
| 種屬 | 人 |
| 別稱 | RS4-11; RS4:11; RS 4;11; RS(4;11); RS411 |
| 組織來(lái)源 | 骨骼,；骨髓 |
| 疾病 | 急性淋巴細(xì)胞白血病ALL |
| 傳代比例/細(xì)胞消化 | 1:2傳代 |
| 培養(yǎng)基配置 | RPMI1640培養(yǎng)基；10%胎牛血清,；1%雙抗 |
| 簡(jiǎn)介 | RS4;11 是從一名患有急性淋巴細(xì)胞白血病的 32 歲白人女性患者的骨髓中分離出來(lái)的淋巴母細(xì)胞系,。 這些細(xì)胞缺乏 表面和細(xì)胞質(zhì)免疫球蛋白 ，并且 CALLA (CD10) 呈陰性,。這些細(xì)胞的髓過(guò)氧化物酶和酯酶也呈陰性 ,，并且不被 蘇丹黑染色。這些細(xì)胞對(duì)末端脫氧核苷酸轉(zhuǎn)移酶 (TdT) 呈強(qiáng)陽(yáng)性 ,，對(duì) BA-1 (CD24),、BA-2 (CD9) 和 MHC II 類抗 原 (HLA DR) 呈陽(yáng)性。 |
| 形態(tài) | 淋巴母細(xì)胞樣 |
| 生長(zhǎng)特征 | 懸浮生長(zhǎng) |
| 倍增時(shí)間 | ~50h |
| 抗原表達(dá) | HLA DR +; CD9 +; CD24 + |
| STR | Amelogenin: X CSF1PO: 11,12 D13S317: 11 D16S539: 11,12 D5S818: 12,13 D7S820: 8,12 THO1: 6,9.3 TPOX: 8 vWA: 14,17 |
| 保藏機(jī)構(gòu) | ATCC; CRL-1873 |
| 備注 | 該細(xì)胞為懸浮細(xì)胞 ,，請(qǐng)注意離心收集細(xì)胞懸液 ,，請(qǐng)勿直接倒掉細(xì)胞培養(yǎng)液。 |
Combination of PD-L1 positive TILs and SII could further refine prognosis in GCTs.An important aspect of malignant progression is the acquired ability of tumor cells to avoid recognition and destruction by the immune system (immune escape). Clinical cancer progression is also associated with the development of tumor hypoxia, which is mechanistically linked to the
采購(gòu)中心
化工儀器網(wǎng)